Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4259-4265

  Ikeda, Takashi ^a   Murakami, Koji ^a   Hayakawa, Yoshihiro ^a   Fujii, Hideki ^a   Ohkoshi, Motohiro ^b   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

FOY 305; Invasion; Serine protease inhibitor

Indexed keywords

CAMOSTAT MESILATE; FIBRIN; FO 349; MATRIGEL; MATRIX METALLOPROTEINASE INHIBITOR; ONO 3403; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSARCOMA; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; ZYMOGRAPHY;

ALLYLGLYCINE; AMIDINES; ANTINEOPLASTIC AGENTS; BENZAMIDINES; BENZOATES; CELL SURVIVAL; FIBROSARCOMA; GABEXATE; GUANIDINES; HUMANS; KINETICS; NEOPLASM INVASIVENESS; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032410114     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hart IR: "Seed and soil" revisited: Mechanisms of site specific metastasis. Cancer Metastasis Rev 1: 5-16, 1982.
2. Liotta LA, Rao CN and Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 49: 636-649, 1983.
3. Fidler IJ: The Ernst W. Bertner Memorial Award Lecture: the evolution of biological heterogeneity in metastatic neoplasms. In: Cancer invasion and metastasis: biologic and therapeutic aspects (Nicolson GL and Milas L, eds.). New York, Raven Press, 1984, pp.5-26.
4. Nicolson GL: Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47: 1473-1487, 1987.
5. Karpathlan S and Pearlstein E: Heterogeneous mechanism of tumor cell-induced platelet aggregation with possible strategy toward prevention of metastasis. In: Hemostasis mechanisms and metastasis (Honn KV and Sloane BF, eds.). Boston, Martinus Nijhoff, 1984, pp.139-169.
6. McCarthy JB and Furcht LT: Laminin and fibronectin promote the haptotactic migration of B16-BL6 mouse melanoma cells in vitro. J Cell Biol 98: 1474-1480, 1984.
7. Terranova VP, Hujanen ES and Martin GR: Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 77: 311-316, 1986.
8. Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L and Graeff H: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 373: 611-622, 1992.
9. Sullivan LM and Quigley JP: An anticatalytic monoclonal antibody to avian plasminogen activator, its effect on behavior of RSV-transformed chick fibroblast. Cell 45: 905-915, 1986.
10. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A and Foidart JM: Involvement of PA/plasmin system in the processing of pro-MMP and in the second step of pro-MMP-2 activation. FEBS J 405: 157-162, 1997.
11. Goldberg GI, Strongin A, Voilier IE, Genrich T and Manner BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583-4591, 1992.
12. Mars WM, Liu ML, Kitson RP, Gordfarb RH, Gabauer MK and Michalopoulos GK: Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration. Hepatology 21: 1695-1701, 1995.
13. Naka D, Ishii T, Yoshiyama Y, Miyazawa K, Hara H, Hishida T and Kitamura N: Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem 267: 20114-20119, 1992.
14. O'Connell JP, Willenbrock F, Docherty AJP, Eaton D and Murphy G: Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metallo-proteinase interactions of gelatinase B. J Biol Chem 269: 14967-14973, 1994.
15. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
16. Tamura Y, Hirano M, Okamura K, Minato Y and Fujii S: Synthetic inhibitor of trypsin, plasmin, kallikrein, thrombin, Cir Cl elastase. Biochim Biophys Acta 484: 417-422, 1977.